Intravitreal triamcinolone acetonide: Potential complications

Daniel Vítor Vasconcelos-Santos, Márcio B. Nehemy, Ryan Mckay Rich, Silvana Negrao, Harry W. Flynn

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Intravitreal injection of triamcinolone acetonide (IVTA) has been used as an off-label strategy in the management of a wide range of edematous, neovascular and inflammatory retinal diseases. Despite the variable success rates achieved in each disease, a variety of adverse events have been reported. These may be associated with the intravitreal injection procedure (endophthalmitis, vitreous hemorrhage and retinal detachment), preservatives in the vehicle of the drug (intraocular toxicity and noninfectious endophthalmitis) and the corticosteroid itself (cataract, ocular hypertension and infection). This article aims to review the incidence and mechanisms of the potential adverse effects of IVTA injection.

Original languageEnglish (US)
Pages (from-to)987-999
Number of pages13
JournalExpert Review of Ophthalmology
Issue number6
StatePublished - Dec 1 2007


  • adverse effects
  • corticosteroids
  • intravitreal injections
  • risk factors
  • triamcinolone acetonide
  • vitreous body

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology
  • Optometry


Dive into the research topics of 'Intravitreal triamcinolone acetonide: Potential complications'. Together they form a unique fingerprint.

Cite this